Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women
Authors:
- Ferdinand RoelfsemaFRFerdinand Roelfsema
- Marijke FrölichMFMarijke Frölich
- Johannes van PeltJPJohannes van Pelt
- Marcel P. M. StokkelMSMarcel P. M. Stokkel
- A. Edo MeindersAMA. Edo Meinders
- Hanno PijlHPHanno Pijl
- 1 November 2006
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 291 (5) , E1038-E1043
Abstract
The metabolic syndrome comprises a cluster of metabolic anomalies including insulin resistance, abdominal obesity, dyslipidemia, and hypertension. Previous studies suggest that impaired dopamine D2 receptor (D2R) signaling is involved in its pathogenesis. We studied the acute effects of bromocriptine (a D2R agonist) on energy metabolism in obese women; body weight and caloric intake remained constant. Eighteen healthy, obese women (BMI 33.2 ± 0.6 kg/m2, mean age 37.5 ± 1.7, range 22–51 yr) were studied twice in the follicular phase of their menstrual cycle in a prospective, single-blind, crossover design. Subjects received both placebo (P; always first occasion) and bromocriptine (B; always second occasion) on separate occasions for 8 days. At each occasion blood glucose and insulin were assessed every 10 min for 24 h, and circadian plasma free fatty acid (FFA) and triglyceride (TG) levels were measured hourly. Fuel oxidation was determined by indirect calorimetry. Body weight and composition were not affected by the drug. Mean 24-h blood glucose ( P < 0.01) and insulin ( P < 0.01) were significantly reduced by bromocriptine, whereas mean 24 h FFA levels were increased ( P < 0.01), suggesting that lipolysis was stimulated. Bromocriptine increased oxygen consumption ( P = 0.03) and resting energy expenditure (by 50 kcal/day, P = 0.03). Systolic blood pressure was significantly reduced by bromocriptine. Thus these results imply that short-term bromocriptine treatment ameliorates various components of the metabolic syndrome while it shifts energy balance away from lipogenesis in obese humans.Keywords
This publication has 38 references indexed in Scilit:
- Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in ratsJournal of Biomedical Science, 2002
- Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob MiceNeuroendocrinology, 2000
- Intracerebroventricular Administration of Bromocriptine Ameliorates the Insulin-Resistant/Glucose-Intolerant State in HamstersNeuroendocrinology, 1999
- Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body WeightEndocrine Reviews, 1999
- α-Blockers in HypertensionCurrent Medical Research and Opinion, 1999
- Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) miceLife Sciences, 1997
- The Role of Dopamine (D2), α and β-adrenoceptor Receptors in the Decrease in Gastrointestinal Transit Induced by Dopamine and Dopamine-Related Drugs in the RatPharmacological Research, 1993
- Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabeticsCellular and Molecular Life Sciences, 1992
- Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleusNeuroscience Letters, 1991
- Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatmentLife Sciences, 1989